WFH Advocates Global Health Equity for Hemophilia at WHO SEA Meeting
World Federation of Hemophilia (WFH), shared a post on LinkedIn:
“During the 78th Session of the WHO Regional Committee for South-East Asia (SEA/RC78) in Colombo, SriLanka, WFH Regional Manager Harshal Kale delivered a powerful statement calling for the effective procurement mechanisms to ensure equitable access to treatment for people with hemophilia and other Bleeding Disorders.
These remarks reinforced the importance of aligning with the 2025 WHO Essential Medicines List and the Delhi Declaration to improve access to essential medical products across the region and beyond.
Kale also voiced the strong support of the WFH for a WHA resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Inherited Bleeding Disorders proposed for discussion at the 158th session of the WHO Executive Board and backed by several Member States including Armenia, Morocco, Nepal and Sri Lanka. The WFH also commends Nepal government for voicing their full support for this resolution in their statement at the SEA/RC78 meeting in Colombo.”

Read the full statement here.
Stay informed with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis